<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649632</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-52120-450</org_study_id>
    <nct_id>NCT04649632</nct_id>
  </id_info>
  <brief_title>Relation Between Dose and Time to Reinjection of Botulinum Toxin-A in Patient With Poststroke Spasticity From a Real-world Healthcare Insurance Database.</brief_title>
  <acronym>Relax</acronym>
  <official_title>Relation Between Dose and Time to Reinjection of Botulinum Toxin-A in Patient With Poststroke Spasticity From a Real-world Healthcare Insurance Database.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determining the mean/median time between botulinum toxin-A injection within the treatment of&#xD;
      patients with spasticity after stroke in relation to the botulinum toxin dose from a&#xD;
      healthcare insurance database in the Netherlands.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2020</start_date>
  <completion_date type="Actual">September 18, 2020</completion_date>
  <primary_completion_date type="Actual">September 18, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean time to next injection per brand</measure>
    <time_frame>From baseline up to end of data collection (January 2012 up to December 2016)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median time to next injection per brand</measure>
    <time_frame>From baseline up to end of data collection (January 2012 up to December 2016)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosing of botulinum toxin-A in daily practice in relation to time to next injection</measure>
    <time_frame>From baseline up to end of data collection (January 2012 up to December 2016)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average cost per year per brand per patient</measure>
    <time_frame>From baseline up to end of data collection (January 2012 up to December 2016)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploring factors like age, gender, time since diagnosis stroke that influence dosing and time between botulinum toxin-A treatments</measure>
    <time_frame>From baseline up to end of data collection (January 2012 up to December 2016)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time interval between 2 injections of the same brand</measure>
    <time_frame>From baseline up to end of data collection (January 2012 up to December 2016)</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">451</enrollment>
  <condition>Post Stroke Spasticity</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients selected from the database claimed within the code 313 will be included in the&#xD;
        descriptive analyses.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A patient will be included if he has a diagnosis stroke within the rehabilitation&#xD;
             setting and has received at least two injections of botulinum toxin-A: Dysport or&#xD;
             Botox&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A patient will be excluded if he has been only treated with Xeomin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ipsen Facility</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2132LS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

